Shield Therapeutics plc

Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company dedicated to developing and commercializing late-stage, hospital-focused pharmaceuticals, primarily addressing iron deficiency in adult patients. Its flagship product, Accrufer® (also known as Feraccru® in certain regions), is an innovative, stable, non-salt oral therapy designed for the treatment of iron deficiency, with or without anemia. The company operates globally, with Accrufer® available in the United States and Feraccru® marketed in the United Kingdom and European Union through established commercial partnerships. Shield Therapeutics has also secured licensing agreements enabling product development and distribution in markets such as China, Hong Kong, Macau, Taiwan, Korea, and Canada. Underpinned by a mission to enhance patient outcomes and quality of life, the company leverages a robust team of industry veterans and a collaborative culture. Shield Therapeutics plc plays a significant role in the healthcare and specialty pharmaceutical sector, focusing on innovative therapies that address unmet needs in iron deficiency management.